English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

[first paragraph of article]The 2003 discovery of proprotein convertase subtilisin–kexin type-9 (PCSK9) – a circulating protein targeting the low density lipoprotein (LDL) receptor for its degradation    – paved the way for the development of several therapeutic approaches which inhibit the protein itself (by monoclonal antibodies) or its RNA (by RNA interference ‘‘RNAi’’).    These drugs are a very promising and attractive therapy for high- risk cardiovascular (CV) patients, patients with statin intolerance, and those with familial hypercholesterolemia.

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors